Journal article
Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
- Abstract:
-
BACKGROUND: Memantine is licensed for moderate-to-severe Alzheimer's disease (AD). National Institute for Clinical Excellence (NICE) guidance does not recommend the use of memantine in combination with cholinesterase inhibitors (acetylcholinesterase inhibitor (AChEI)). The underpinning meta-analysis was disputed by the manufacturer. OBJECTIVES: To compare the efficacy of AChEI monotherapy with combination memantine and AChEI therapy in patients with moderate-to-severe AD and to examine the i...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Version of record, pdf, 372.6KB)
-
- Publisher copy:
- 10.1136/bmjopen-2012-000917
Authors
Bibliographic Details
- Publisher:
- BMJ Publishing Group Publisher's website
- Journal:
- BMJ Open Journal website
- Publication date:
- 2012-01-01
- Acceptance date:
- 2012-03-30
- DOI:
- EISSN:
-
2044-6055
- ISSN:
-
2044-6055
Item Description
- Language:
- English
- Keywords:
- UUID:
-
uuid:6cf40af2-9543-4127-a9ad-69ca42a929b9
- Local pid:
- pubs:339870
- Source identifiers:
-
339870
- Deposit date:
- 2013-11-16
Terms of use
- Copyright holder:
- Farrimond et al
- Copyright date:
- 2012
- Notes:
- © 2012 Farrimond et al. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record